Skip to main content
. Author manuscript; available in PMC: 2010 Jun 1.
Published in final edited form as: Atherosclerosis. 2008 Sep 27;204(2):418–423. doi: 10.1016/j.atherosclerosis.2008.09.016

Figure 3.

Figure 3

Results from in vitro cholesterol efflux study. Cholesterol efflux capacity of plasma from human apoA-I transgenic mice treated with nevirapine and efavirenz. Bone marrow-derived macrophages were isolated from wild-type mice and differentiated with DMEM/ FBS/10% L929 cells for 8 days. Cells were labeled with [3H]-cholesterol for 24 hours and loaded with 25ug/ml of acetylated LDL at the same time. After the incubation, efflux was initiated on the addition of 2.5% control mouse plasma, nevirapine-treated plasma and efavirenz-treated plasma. (* p=0.01).